The prospective, multicenter, double-blind study presented in this report evaluated whether or not intravenous (IV) administration of doripenem, a carbapenem with bactericidal activity against gram-negative and gram-positive uropathogens, is inferior to IV administration of levofloxacin in the treatment of complicated urinary tract infection (cUTI). Patients (n ‫؍‬ 753) with complicated lower UTI or pyelonephritis were randomly assigned to receive IV doripenem at 500 mg every 8 h (q8h) or IV levofloxacin at 250 mg q24h. Patients in both treatment arms were eligible to switch to oral levofloxacin after 3 days of IV therapy to complete a 10-day treatment course if they demonstrated significant clinical and microbiological improvements. The microbiological cure rate (primary end point) was determined at the test-of-cure (TOC) visit occurring 5 to 11 days after the last dose of antibiotic. For the microbiologically evaluable patients (n ‫؍‬ 545), the microbiological cure rates were 82.1% and 83.4% for doripenem and levofloxacin, respectively (95% confidence interval [CI] for the difference, ؊8.0 to 5.5%); in the microbiological modified intent-to-treat cohort (n ‫؍‬ 648), the cure rates were 79.2% and 78.2%, respectively. Clinical cure rates at the TOC visit were 95.1% in the doripenem arm and 90.2% in the levofloxacin arm (95% CI around the difference in cure rates [doripenem cure rate minus levofloxacin cure rate], 0.2% to 9.6%). Both treatment regimens were generally well tolerated. Doripenem was found not to be inferior to levofloxacin in terms of therapeutics and is now approved for use in the United States and Europe for the treatment of adults with cUTI, including pyelonephritis. As fluoroquinolone resistance increases, doripenem may become a more important option for successful treatment of cUTIs, including treatment of pyelonephritis.
Urinary tract infections (UTIs) are the leading cause of gram-negative bacteremia for patients of all ages and can be associated with a high risk of morbidity and mortality, especially in the elderly, for whom they can account for nearly 25% of all infections (2) . UTIs are responsible for nearly 7 million office visits and 1 million emergency department visits, which result in 100,000 hospitalizations each year, in the United States alone (2, 22) and account for at least 40% of all nosocomial infections (22, 23) . Complicated lower UTIs (cLUTIs) and complicated pyelonephritis occur in patients who have a functionally, metabolically, or anatomically abnormal urinary tract. Unlike the narrow and predictable spectrum of pathogens associated with uncomplicated UTIs, a broad range of bacteria can cause complicated infections, and many are resistant to multiple antimicrobial agents (22) . For patients with complicated UTIs (cUTIs) requiring intravenous (IV) antibiotic therapy, empirical treatment with a broad-spectrum antibiotic can help avoid the unnecessary risk and cost of disease progression associated with treatment failure.
Fluoroquinolones are indicated for the management of acute uncomplicated UTIs as well as cUTIs and pyelonephritis for adults, but uropathogen resistance to them is increasing (20) . The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) surveillance program demonstrated increasing rates of fluoroquinolone resistance in bacterial isolates from U.S. medical centers, especially among Escherichia coli, Enterobacter, Proteus mirabilis, and indole-positive Proteae spp. (17) . Resistance to ciprofloxacin and levofloxacin in E. coli reached 21.6% and 20.4%, respectively, of isolates tested in 2005 (16) . In the North American Urinary Tract Infection Collaboration Alliance surveillance study, 5.5% and 5.1% of urinary E. coli isolates from outpatients in the United States and Canada were resistant to ciprofloxacin and levofloxacin, respectively (24) . Similar results were reported for a cohort in Israel (12) . Pseudomonas aeruginosa fluoroquinolone resistance is also problematic, with rates now exceeding 35% (7) . As fluoroquinolone resistance increases, alternative therapies will become more important for successful treatment of cUTIs, particularly for patients at risk for infection with fluoroquinolone-resistant pathogens.
Doripenem is a broad-spectrum carbapenem that has been approved for use in the United States and Europe for the treatment of adults with cUTIs, including pyelonephritis, and for the treatment of complicated intra-abdominal infections. It has also been approved in Europe for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. Doripenem is primarily eliminated by the kidneys and is concentrated in the urine (Doripenem package insert; OrthoMcNeil Pharmaceutical, Inc., Raritan, NJ). It has potent in vitro activity against the gram-negative aerobic bacteria commonly encountered in cUTIs, including E. coli, other members of the Enterobacteriaceae, and P. aeruginosa (3, 22) . Like other carbapenems, doripenem is resistant to hydrolysis by a variety of ␤-lactamases, including extended-spectrum ␤-lactamases (ESBLs). Several in vitro studies have shown that doripenem has greater activity than other carbapenems against recent isolates of key gram-negative pathogens, including ESBL-producing strains of E. coli and P. aeruginosa (8, 10, 11) . Moreover, under experimental conditions, doripenem was less likely than other carbapenems to select for carbapenem-resistant mutants of P. aeruginosa (14, 19) . This profile makes doripenem an attractive agent for the treatment of cLUTIs and pyelonephritis. Doripenem has moderate activity against Enterococcus faecalis (4, 9) , with MIC 90 values of 4 to 16 g/ml, i.e., one dilution lower than ertapenem and meropenem. Most current clinical isolates of Enterococcus faecium are resistant to doripenem.
This trial was designed in compliance with Food and Drug Administration guidelines for registration studies to compare the microbiological and clinical cure rates of patients with cUTIs who received at least 3 days of IV doripenem or IV levofloxacin therapy, with an option for patients in both treatment arms to switch from IV therapy to oral levofloxacin if specified favorable clinical and microbiological criteria were satisfied.
MATERIALS AND METHODS
Patients. Men and women aged 18 years or older with cLUTI or pyelonephritis (complicated or uncomplicated) were eligible to enroll if they met clinical and microbiological criteria for the diagnosis of cLUTI or pyelonephritis and if they required initial treatment with a parenterally administered antibacterial agent. All patients were required to have provided a baseline urine specimen within 48 h before the start of treatment that, when cultured, grew at least one and not more than two bacterial uropathogens at Ն10 5 CFU/ml. Blood was obtained for culture from all patients who presented with clinical signs or symptoms of pyelonephritis or bacteremia (fever and/or signs and symptoms of sepsis) and from all catheterized patients from whom the baseline urine specimen was obtained through the catheter. Urine cultures growing more than two pathogens were considered contaminated. However, if a patient with a contaminated urine specimen had the same pathogen cultured from both urine (at Ն 10 5 CFU/ml) and blood, then that pathogen isolated from both sources was considered causative. To be diagnosed as having symptomatic cLUTI, patients must have had at least one UTI symptom (dysuria, frequency, suprapubic pain, or urgency) and at least one complicating factor (male gender, current bladder instrumentation or indwelling catheter that was to be removed during IV study drug administration, obstructive uropathy that was to be medically or surgically treated during IV study drug administration, urogenital surgery within 7 days of the first dose of study drug, or a functional or anatomical urogenital tract abnormality with a voiding disturbance). Patients who were not able to perceive symptoms for reasons such as spinal cord injury were diagnosed with asymptomatic cLUTI if they provided two baseline cultures that grew the same organism at Ն 10 5 CFU/ml. To be diagnosed with pyelonephritis, patients were required to have had a documented fever of Ն37.8°C (oral) and flank pain or costovertebral angle tenderness. Complication criteria for pyelonephritis were the same as those for cLUTI.
Patients excluded from the study were those with a history of moderate or severe hypersensitivity to ␤-lactam or quinolone antibiotics, those with a urinary catheter that would not be removed (or with an expectation that one would be inserted and not removed) during the study, and those with complete permanent obstruction of the urinary tract, a permanent indwelling bladder catheter, or comparable instrumentation, including a nephrostomy. Patients with a confirmed fungal UTI (Ն10 3 CFU/ml) at study entry, with a suspected or confirmed perinephric or intrarenal abscess, with suspected or confirmed prostatitis, with severe renal dysfunction requiring dialysis, with known ileal loops or vesico-uretral reflux, or with any rapidly progressive or immediately life-threatening illness were excluded. Patients were excluded if they had a concomitant infection(s) requiring systemic antimicrobial therapy in addition to the IV study drug or an intractable cUTI(s) expected to require more than 10 days of IV treatment or if they had received any potentially therapeutic antibiotic for the treatment of the UTI within the 96 h before providing the baseline urine culture specimen or subsequently before the first dose of study drug was administered. Patients were excluded if they had a severely immunocompromising illness or if they were receiving immunosuppressive therapy, including cancer chemotherapy and medications to prevent the rejection of a transplanted organ. Patients with a central nervous system disorder predisposing them to seizures or a lowered seizure threshold were excluded (in compliance with the levofloxacin label), as were those with a severely abnormal liver function test result (for aspartate transaminase or alanine transaminase) more than three times the upper limit of the normal range, neutropenia (Ͻ500 cells/l), thrombocytopenia (Ͻ40,000 platelets/l), or low hematocrit (Ͻ20%). Patients participating in a study of any investigational drug or device within the preceding 30 days or in a different study of doripenem were excluded, as were women who were pregnant, nursing, or of childbearing potential and not practicing an effective birth control method. If an investigator thought that either the safety of the patient or the quality of the study data might be compromised, the patient was excluded from participation.
Study design. This phase III, multicenter, prospective, randomized, doubleblind study was conducted from December 2003 to March 2006 at 44 investigational centers in North America, South America, and Europe (18 centers in the United States, 7 in Germany, 7 in Argentina, 6 in Brazil, 5 in Poland, and 1 in Canada). An institutional review board or independent ethics committee at each study center reviewed and approved the protocol and the informed consent form prior to the enrollment of any patients at that center. The protocols of this study followed the ethical principles of the Declaration of Helsinki and the guidelines of good clinical practices and all applicable regulatory statutes. All patients or their legally acceptable representatives provided written informed consent.
At the screening (within the 48 h prior to administration of the first dose of the study drug therapy), all patients provided urine for culture, and patients who were suspected to have bacteremia also had blood drawn for culture. Investigators were permitted to administer the IV study drug before the results of the patient's baseline urine culture were known, but patients were to be withdrawn from the study if the culture did not grow a qualifying bacterial uropathogen at Ն10 5 CFU/ml. Eligible patients were assigned to a study therapy regimen according to a computer-generated randomization code by the use of an interactive voice response system. Patients were stratified by region (North America, South America, or Europe) and, within each region, by baseline diagnosis (cLUTI or pyelonephritis) and then randomly assigned at a 1:1 ratio to receive 500 mg of IV doripenem (Doribax [manufactured by Shionogi & Co., Ltd., Osaka, Japan; distributed by Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ]) every 8 h (q8h) or 250 mg of IV levofloxacin (Levaquin [Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ]) q24h. The treatment assignment was conducted in a blinded fashion with respect to patients and all study personnel (including the sponsor), with the exception of the study site pharmacists. Using a double-dummy design, each study drug and its respective placebo were administered as a 1-h IV infusion. The order of study drug infusions (doripenem or its placebo followed by levofloxacin placebo or levofloxacin and vice versa) was also randomized. Patients were to receive the IV study drug for a minimum of nine treatment administrations (approximately 72 h) and could subsequently be switched to oral levofloxacin (250 mg administered once daily) if no fever were present for at least 24 h, if signs and symptoms of cUTI were absent or improved from baseline levels, and if at least one urine culture showed no growth or a colony count of Ͻ10 4 CFU/ml and no subsequent cultures grew a uropathogen at Ն10 4 CFU/ml. For patients who were switched to oral antibiotic therapy, the first dose of oral levofloxacin was given 8 to 12 h after administration of the last dose of the IV study drug. The total duration of the study drug therapy (IV study drug only or IV study drug followed by oral levofloxacin) was 10 days. The dosage of study drug was adjusted for patients with impaired renal function. Patients with documented bacteremia who had been randomly assigned to receive doripenem continued to receive 500 mg q8h; patients who had been randomly assigned to receive levofloxacin were permitted to have the dose increased to 500 mg q24h at the discretion of the investigator. For bacteremic patients in both study arms, oral levofloxacin administration could be increased to 500 mg q24h, and the total duration of study drug therapy could be extended to 14 days.
During therapy, urine specimens were collected daily until two consecutive urine cultures with no growth (colony count of Ͻ10 4 CFU/ml) at 24 h were reported. For patients with positive blood cultures at the screening, blood samples were obtained daily until two consecutive blood cultures showed no growth. Clinical assessments of UTI symptoms and safety evaluations were performed daily during the IV study drug administration (including at the end of the IV study drug therapy [EOT IV]); at the test-of-cure (TOC) visit, which occurred 5 to 11 days after the last dose of the study drug; and at the late follow-up (LFU) visit, which occurred 28 to 42 days after the last dose.
VOL. 53, 2009 DORIPENEM FOR COMPLICATED URINARY TRACT INFECTIONS 3783
All urine and blood culture specimens were cultured in local laboratories. All uropathogens isolated at Ն10 3 CFU/ml and all cultured blood pathogens were identified at the local laboratories (urine pathogens were also quantified), stored frozen, and shipped to a designated central laboratory (Eurofins Medinet [formerly Focus Bio-Inova, Inc.], Herndon, VA) for validation of identification and comprehensive susceptibility testing.
Outcome assessments. Patients were considered to have completed the study if they received study drug therapy for 10 days and completed all assessments at the TOC and LFU visits or if they completed at least 3 days of IV study drug therapy and were classified as a microbiological or clinical failure prior to the TOC visit. The microbiological and clinical responses to treatment were determined independently of one another at the EOT IV, TOC, and LFU visits. Microbiological cure was designated to have occurred when the baseline uropathogen(s) was reduced from Ն10 5 CFU/ml at the baseline to Ͻ10 4 CFU/ml without the use of adjunctive nonstudy antibacterial therapy. The clinical outcome was determined by the investigator and considered a cure if signs or symptoms of cLUTI or pyelonephritis (fever, flank pain, costovertebral angle tenderness, suprapubic pain, dysuria, and urgency or frequency of urination) improved or resolved or returned to preinfection status (if known) and if nonstudy antibacterial therapy had not been administered for the treatment of the baseline urinary infection. Outcomes that could not be determined were counted as failures.
Emergent infections were considered to have occurred when a urine culture grew Ն10
5 CFU of a uropathogen/ml, including any causing a fungal infection, other than the baseline uropathogen during (superinfection) or after (new infection) the course of study drug therapy. Emergent infections were not counted as failures when determining microbiological outcome.
Populations for analysis. The intent-to-treat (ITT) population included all patients who received any dose or partial dose of a study drug for therapy. The microbiologically modified ITT (mMITT) population was the subset of patients in the ITT population who had baseline urine culture results qualifying them for participation in the study, regardless of the susceptibility of the baseline uropathogen(s) to either study drug. Microbiologically evaluable (ME) patients met the protocol definition of cUTI, had a bacterial uropathogen (Ն10 5 CFU/ml) isolated from a baseline urine culture, were compliant with study drug therapy or were classified as an evaluable failure after completing at least 3 days of IV study drug therapy, had no significant protocol deviation from the inclusion-exclusion criteria or in-study procedures (including previous or concurrent antibiotics), and had an interpretable urine culture result at the specified visit. Only ME patients who had a favorable response for the TOC assessment were eligible for inclusion in the analysis of microbiological outcome at the LFU visit. Clinically evaluable (CE) patients had to meet the same criteria as ME patients, except that a clinical assessment at the specified visit was required and an interpretable urine culture was not. Patients enrolled with asymptomatic cLUTI were excluded.
Safety assessments. Patients in the ITT population were monitored for adverse experiences daily during parenteral therapy and for 30 days after administration of the last dose of the study drug. The investigator assessed the severity of each event and its likelihood of being related to the study drug.
Statistical analysis. The study was designed to demonstrate that IV doripenem was not inferior to IV levofloxacin with respect to the per-subject microbiological cure rate at the TOC in the ME analysis set. The sample size was based on an expected microbiological cure rate of 84% for both doripenem and levofloxacin. A sample of approximately 248 ME patients per treatment arm was required to demonstrate that IV doripenem was not inferior to IV levofloxacin, with the power of the determination of the results at 85% and a one-sided 2.5% significance level. On the basis of an assumption that 66% of enrolled patients would be ME at the TOC visit, a sample size of at least 375 patients per treatment arm was required. The coprimary efficacy end point was the microbiological cure rate in the mMITT population. An absence of inferiority was to be concluded if the lower limit of the two-sided 95% confidence interval (CI) for the difference (doripenem data minus levofloxacin data) in the results obtained for patients classified as representing microbiological cures was ՆϪ10%. This difference and its 95% CI were obtained using the continuity-adjusted normal approximation to the difference between two binomial proportions, according to the Wald method. Results for various subgroups were tabulated. The secondary efficacy end points were the clinical cure rate at the TOC visit for the CE population and the microbiological cure rate for the ME patients infected with E. coli. Patients whose microbiological response data at the TOC visit were indeterminate or missing were considered nonevaluable and were excluded from the ME analysis set unless they had been assessed as treatment failures earlier. The microbiological responses for such patients were counted as failures in the mMITT co-primary analysis set.
RESULTS

Patient disposition.
A total of 753 patients with cUTI were enrolled and randomly assigned to treatment with IV doripenem (n ϭ 377 [50.1%]) or IV levofloxacin (n ϭ 376 [49.9%]) (Fig. 1) . The two treatment arms were similar with respect to the number of patients included and the reasons for exclusion (Fig. 1) . Only five randomized patients received no study drug. The most frequent reason for exclusion from the mMITT population was a lack of a qualifying baseline urine culture; for those excluded from the ME population, the two primary reasons were lack of compliance with the study therapy and violation of the TOC window of time.
Demographics and baseline characteristics. The two treatment arms were well matched with respect to demographic and baseline characteristics of the randomized patients (Table 1) . Overall, the randomized population was predominantly female (61.6%) and Caucasian (79.4%), with a mean age of 51 years. Approximately 35% of patients were Ն65 years old, and approximately 15% were Ն75 years old. Almost half (48%) of the patients in each group had a baseline diagnosis of cLUTI, with 66 (8.8%) patients overall having complicated pyelonephritis and 58 (7.7%) patients having concurrent bacteremia at baseline. The rates of incidence of normal, mild, moderate, and severe renal impairment were similar in the doripenem and levofloxacin arms. The ME population (n ϭ 545) demographics closely resembled the proportionality of those of the randomized population. Approximately half of the patients in each group had a baseline diagnosis of cLUTI (50.6%), with 48 patients (8.8%) overall having complicated pyelonephritis and 43 patients (7.9%) having concurrent bacteremia at the baseline.
Baseline uropathogens. The distributions of baseline uropathogens in the two treatment arms were generally similar ( Table 2 ). E. coli was the most frequently isolated uropathogen, being identified in urine samples from 477 of 648 patients (73.6%) of the mMITT population. Other pathogens identified were P. mirabilis in urine samples from 42 (6.5%) patients, Klebsiella pneumoniae in urine samples from 32 (4.9%) patients, and P. aeruginosa and Enterobacter cloacae in urine samples from 18 (2.8%) patients each. Only three baseline isolates (one E. faecalis, one E. faecium, and one Staphylococcus aureus) showed a doripenem MIC of Ն16 g/ml. In comparison, 96 isolates, including 48 of 457 (10.5%) tested isolates of E. coli, 10 of 42 (23.8%) isolates of P. mirabilis, 3 of 27 (11.1%) isolates of K. pneumoniae, 10 of 17 (58.8%) isolates of E. cloacae, and 9 of 16 (56.3%) isolates of P. aeruginosa, were resistant to levofloxacin per Clinical and Laboratory Standards Institute guidelines.
Exposure to study drug. The mean durations of study drug therapy (IV only or IV and oral) were 9.5 days in the doripenem arm and 9.1 days in the levofloxacin arm. IV doripenem was administered for a mean of 5.4 days and IV levofloxacin for 5.3 days. Oral levofloxacin was taken for mean durations of 6.0 days and 6.1 days in the doripenem and levofloxacin arms, respectively. For 70.4% (530/753) of randomized patients, the switch was made from IV to oral therapy; 8.8% (33/377) of IV doripenem patients and 9.0% (34/376) of IV levofloxacin patients received only the IV study drug without being switched to oral levofloxacin treatment.
Microbiological cure rates. The primary efficacy analysis (Fig. 2) demonstrated that the ME population achieved microbiological cure rates of 82.1% (230/280) and 83.4% (221/265) with doripenem and levofloxacin, respectively; patients in the mMITT population achieved microbiological cure rates of 79.2% (259/327) and 78.2% (251/321), respectively. In these co-primary efficacy analyses, the lower limit of the CI for the difference between treatments was within the protocol-specified margin of ՆϪ10%, demonstrating that doripenem was not therapeutically inferior to levofloxacin for the treatment of cUTI, including pyelonephritis.
In the ME population, the microbiological cure rates at the EOT IV were 100% (274/274) for the doripenem-treated patients and 88% (229/259) for the levofloxacin-treated patients (P Ͻ 0.001), suggesting that the noninferior response demonstrated for the doripenem-treated patients at the TOC visit could be attributed to the IV portion of the therapeutic regimen, independently of a switch to oral levofloxacin. The microbiological cure rates were sustained in the doripenem (89% [185/209]) and levofloxacin (90% [186/207]) arms among ME patients at the LFU visit.
In a post hoc analysis evaluating outcomes for patients who received only an IV study drug, the microbiological cure rate at EOT IV was 100% (31/31) with doripenem and 44% (21/48) Subgroup analyses (based on demographic and clinical characteristics) of ME patient microbiological cure rates were generally comparable between treatment arms in subgroups having at least 30 patients per treatment regimen ( Table 3 ). The microbiological cure rate appeared to be higher for patients with a baseline diagnosis of pyelonephritis than for those with cLUTI, most likely because most (87.0%) patients with cLUTI had at least one complicating factor within the urinary tract that persisted throughout the treatment period whereas 82% of the patients with pyelonephritis were considered to have an uncomplicated condition. Although the small subgroup consisting of patients with complicated pyelonephritis appeared to have a higher microbiological cure rate in the levofloxacin arm, the observed numerical differences were within normal sampling variations.
All but one of the patients in each treatment arm who were bacteremic at study entry were microbiologically cured of their cUTI at the TOC visit.
Clinical cure rates. In the CE population, the clinical cure rates at EOT IV were 98.3% (281/286) and 93.2% (240/266) in the doripenem and levofloxacin arms, respectively. At the TOC visit, the clinical cure rates were 95.1% (272/286) and 90.2 (240/266), respectively ( Fig. 3 ) (95% CI for the differences in cure rates [represented by doripenem values minus levofloxacin values], 0.2% to 9.6%). For the subgroup of patients with cLUTI, clinical cure rates at the TOC visit were higher for patients treated with doripenem than for those treated with levofloxacin (95.0% versus 84.7%; P ϭ 0.006); however, similar clinical cure rate differences were seen between treatment groups for patients with pyelonephritis (95.2% versus 95.1%, respectively). Clinical cure rates at the LFU visit of 90.8% (228/251) for the doripenem-treated patients and 95.2% (218/ 229) for the levofloxacin-treated patients who were CE were sustained. For the patients who received the IV study drug only, the clinical cure rates at the TOC visit were 78.1% (25/32) with doripenem and 52.3% (23/44) with levofloxacin. The clinical cure rate was 100% for all 47 patients from both study drug arms who were bacteremic at the baseline stage.
Concordance of microbiological and clinical outcomes. Outcomes at the TOC visit for patients who were both ME and CE were assessed for concordance ( Table 4) . The proportions of patients who were both microbiologically and clinically cured were similar for the two treatment groups: for the doripenemtreated patients, 82.5% (221/271); and for the levofloxacintreated patients, 84.2% (229/253). However, the proportion of patients who were both microbiological and clinical failures (i.e., those with symptomatic bacteriuria) was higher in the levofloxacin group (8.3% for the levofloxacin treatment group versus 1.8% for the doripenem treatment group [P Ͻ 0.001]). Less than 2% of the patients in both study groups had discordant outcomes with respect to microbiological cure and clinical failure, whereas 14.8% (40/271) of patients in the doripenem group and 6.3% (16/253) in the levofloxacin group had outcomes of microbiological failure and clinical cure (i.e., the patients with asymptomatic bacteriuria) at the TOC visit.
Outcomes by pathogen. Doripenem and levofloxacin are both renally excreted, and the levels of both drugs found in the urine exceeded the highest MIC encountered in this study. Table 5 presents microbiologic outcomes in relation to MIC values for the most prevalent (Ն10 isolates) organisms from patients in the ME analysis sets. Microbiological cure rates for the two treatment groups for infections by common uropathogens, including E. coli, K. pneumoniae, and P. mirabilis, were generally comparable (Fig. 4) .
The microbiological cure rates for E. coli infections of ME patients at the TOC visit were 84.4% for the doripenem arm and 87.2% for the levofloxacin arm (P ϭ 0.83) (Fig. 4) . In vitro susceptibility testing revealed that levofloxacin-resistant strains accounted for 10% of the E. coli isolates in both treatment arms. For patients with levofloxacin-resistant E. coli at the baseline stage, the cure rate was 55% (11/20) for the doripenem arm compared with 29% (6/21) for the levofloxacin arm. Among patients with a levofloxacin-resistant E. coli infection who presented with microbiological cure failures at the TOC visit (and who were CE at the TOC visit), a clinical cure rate of 86% (6/7) was seen for those treated with doripenem compared with 33% (4/12) for those treated with levofloxacin. Follow-up blood cultures obtained from all but one of the patients who were bacteremic at the baseline produced no growth. Results for postbaseline blood cultures for one patient in the levofloxacin mMITT analysis set whose samples (both urine and blood) grew E. faecalis at the baseline were not reported; the patient was withdrawn from the study by the investigator.
Some patients for whom therapy failed in both treatment arms harbored uropathogens that developed a fourfold increase in drug MIC during therapy ( Table 6 ). None of the three pathogens in the doripenem arm developed a drug MIC of Ͼ1 g/ml, but in the levofloxacin treatment arm, seven patients harbored a pathogen with a drug MIC Ն 1; the pathogen infecting three of those patients developed a drug MIC ϭ 16 g/ml.
Emergent infections. Superinfections occurred in four patients in the doripenem treatment arm and two patients in the levofloxacin treatment arm; new infections were identified in 23 and 17 patients in the respective arms. E. faecalis was the most common new pathogen (n ϭ 15). In the doripenem arm, only one new infection was caused by a doripenem-resistant Enterococcus avium strain, with a drug MIC ϭ 128 g/ml. In comparison, five new infections in the levofloxacin treatment arm were caused by levofloxacin-resistant organisms: two by E. faecalis (drug MIC ϭ 16, 64) and one each by E. coli (drug MIC ϭ 32), P. mirabilis (drug MIC ϭ 32), and P. aeruginosa (drug MIC ϭ 32). Safety. The rates of incidence and types of all treatmentemergent adverse events (TEAEs) and of those considered by the investigators to be drug related were similar for both treatment groups (Table 7) . Most events were mild or moderate in severity and were attributed by the investigators to the underlying baseline infection or to its complications. Headache was the most common TEAE for both treatment groups, and gastrointestinal disorders were also commonly reported for both groups. Asymptomatic bacteriuria was reported more frequently for patients in the doripenem treatment arm. Reporting of this event was influenced by data collection and verification procedures that occurred during the study, and the reported data represent the similar microbiological failure rates but higher clinical cure rates for patients treated with doripenem. Serious TEAEs occurred with 43 (5.7%) patients, including 28 (7.4%) patients in the doripenem arm and 15 (4.0%) patients in the levofloxacin arm, but none of these events was considered by the investigators to be related to study drug treatment. Discontinuations caused by TEAEs occurred during IV therapy for two (0.5%) doripenem-treated patients and for 11 (2.9%) IV levofloxacin-treated patients. Laboratory assessments reflected the underlying clinical conditions and were similar for both treatment arms. A single seizure was reported, and it occurred in the levofloxacin treatment group; it was not considered by the investigator to be study drug related.
DISCUSSION
The results of this study show that IV doripenem treatment at 500 mg q8h is microbiologically and clinically effective and well tolerated by patients with cUTI, including pyelonephritis, and by patients with concurrent bacteremia and that the dosing regimen administered was not therapeutically inferior to IV levofloxacin treatment at 250 mg q24h.
This study was conducted as a registration trial as part of a program designed to obtain authorization to market doripenem for the treatment of patients with cLUTI and pyelonephrititis. As such, the study design, patient population, end points, and prespecified margin of noninferiority were in compliance with health authority guidance documents. In addition, consideration was given to current medical practice and the need to switch patients to oral therapy as soon as possible to facilitate discharge from the hospital. Therefore, patients were started on IV doripenem or IV levofloxacin treatment but were eligible to switch to oral therapy after 3 days of IV therapy if they met predefined criteria demonstrating microbiological and clinical improvement. Consequently, in the majority of cases, patients assigned to the doripenem arm completed their treatment regimen with oral levofloxacin. However, microbiological and clinical cure rates at the EOT IV were higher in the doripenem treatment arm than in the levofloxacin treatment arm, suggesting that doripenem was at least as effective as on June 25, 2017 by guest http://aac.asm.org/ levofloxacin during the IV portion of the study. In addition, in a post hoc comparison of the treatment arms for patients who received only IV therapy, the microbiological cure rate and E. coli cure rate were numerically higher with IV doripenem and the clinical cure rate was substantially higher with IV doripenem than with IV levofloxacin. These findings support the conclusion that doripenem treatment was not inferior to IV levofloxacin treatment and that the efficacy measured in the doripenem arm was not dependent on the use of oral levofloxacin.
Levofloxacin was selected as a comparator agent for this study because it reaches high concentrations in the urine and in urogenital tissues and has been approved and is widely used for the treatment of cUTI and pyelonephritis in the geographical regions in which this multinational study was conducted. The levofloxacin dosing regimen of 250 mg q24h for 10 days was FIG. 4 . Microbiological eradication rates for ME patients at the TOC visit for most common baseline uropathogens (incidence Ն 10 in the doripenem arm). chosen to reflect the labeled regimen that is most consistently approved globally. Although some experts, societies, and regulatory agencies have recently proposed using a higher dose of levofloxacin, we are not aware of any head-to-head trial comparing clinical outcomes for patients administered 250-mg doses versus 500-mg (or higher) doses. However, investigators in this study were allowed to increase the dose of levofloxacin to 500 mg q24h for subjects who had systemic infections (i.e., bacteremia) at the baseline. All but two subjects with bacteremia presented with pyelonephritis, and microbiological eradication rates for the subgroup of subjects with pyelonephritis who received 250-mg doses of levofloxacin were similar to those seen with subjects who received at least one 500-mg dose (data not shown). Favorable outcomes in this study were lower than those reported in some previously published studies of ␤-lactam antibiotics (6, 21) . However, unlike the previously published studies, for which at least one baseline pathogen had to be susceptible to both parenterally administered study drugs in order for the patient to be evaluable, the susceptibility of the baseline pathogen to the drugs tested was not taken into consideration in this study. This approach more closely mimics clinical practice, where susceptibility results are not always determined in a timely manner. When data from this study were reanalyzed by excluding pathogens resistant to either study drug, favorable microbiological outcomes increased to Ͼ87% for both study arms (data not shown). Thus, the differences in analytic approaches explain, at least in part, why rates of favorable outcome in this study appear to be lower than those reported for previous studies of ␤-lactam antibiotics.
Patients who did not present with classic symptoms but required IV antibiotic therapy for difficult-to-treat cUTI, such as those with a spinal cord injury, were initially allowed to enroll with a diagnosis of asymptomatic cLUTI. However, as enrollment progressed, outcomes for many of these patients could not be determined (due to the lack of an interpretable urine culture, a need to administer a non-study drug antibiotic to treat another infection, the presence of other complex medical conditions, and the use of therapies that confounded interpretation of the safety and efficacy data). As a result of these challenges, patients with asymptomatic cLUTI were subsequently excluded from enrollment.
Classically, registration studies evaluating antibiotics for the treatment of UTI have included the determination of a microbiological end point, either independently or in combination with clinical symptoms. For the patients with asymptomatic cLUTI enrolled in this study, clinical symptoms could not be assessed. Therefore, the primary analysis for this study assessed microbiological outcomes that were independent of clinical symptoms. However, outcomes for patients who were both ME and CE were assessed for concordance at the TOC visit. As expected, few patients were found to be microbiologically cured but assessed as clinical failures (Ͻ2% for both groups); microbiological cure was predictive of improvement in clinical symptoms. However, the lack of clinical symptoms was not necessarily predictive of microbiological outcome. In this study, 15% of patients in the doripenem treatment arm and 6% in the levofloxacin treatment arm had asymptomatic bacteriuria (represented by microbiological failure and clinical cure) at the TOC visit. Since the microbiological failure rates were similar for the two treatments (17% and 15%), the disproportionate incidence of asymptomatic bacteriuria seen in the doripenem treatment group was reflective of the lower rate of clinical cure seen with levofloxacin treatment (96% versus 91%).
E. coli was the most frequently isolated baseline uropathogen and was identified in samples from nearly three-quarters of the study cohort. Susceptibility testing revealed that approximately 10% of the E. coli isolates in both treatment arms were resistant to levofloxacin, a rate which is lower than the 20% rate found in the MYSTIC surveillance program during 2005 in North America (17) . In the present study, doripenem was not statistically superior to levofloxacin in curing patients infected with E. coli. This finding may have been due in part to the lower-than-expected number of levofloxacin-resistant E. coli isolates collected from members of both treatment arms.
The 10% levofloxacin resistance rate for the E. coli isolates seen in this study falls between the 5% rate of levofloxacin resistance found in E. coli isolates from outpatients with UTIs in the North American Urinary Tract Infection Collaboration [4/12] ). All patients with levofloxacinresistant organisms had negative urine cultures at the end of IV doripenem therapy, indicating that microbiological failure of treatment for these patients might not have been due to failure of doripenem therapy to clear these organisms from the urine but might rather represent recurrences or relapses some time after the IV antibiotic treatment was discontinued. It is possible that the relatively lower response rate seen with these patients at the TOC visit was due to conditions that predisposed these patients to infections that were more difficult to cure and/or to an increased susceptibility to reseeding of their urinary tract. Notably, the greater proportion of patients infected with levofloxacin-resistant E. coli were male, were older than 65 years of age, and had cLUTI. Over 80% of these patients had a prior urological history that would have predisposed them to difficult-to-treat infections, such as an enlarged prostate or the presence of a stone or other a foreign body in the urinary tract. Approximately one-third of the patients had a history of recurrent UTI, and prior use of antibiotics was evidenced by the relatively high rate of multidrug-resistant pathogens isolated. Of the 49 fluoroquinolone-resistant E. coli isolates, none were resistant to doripenem, but 15 (31%) were resistant to three or more classes of antibiotics and would be considered multidrug resistant (18) . Thus, with the rise in fluoroquinolone resistance, there is now and will be in the future a strong need for new antibiotics that can be used for the initial empirical treatment of cUTI or when coverage of known fluoroquinolone-resistant strains is needed. The present report suggests the efficacy of IV doripenem in this setting. This study enrolled patients with cLUTI or pyelonephritis and was the first registrational study that we are aware of that evaluated outcomes for patients with complicated versus uncomplicated pyelonephritis. The patients with cLUTI and complicated pyelonephritis had at least one complicating factor that was expected to persist throughout the treatment period, and, as expected for patients with an underlying urinary tract abnormality, the microbiological cure rates were lower for patients with complicated disease in the doripenem and levofloxacin arms, respectively (Table 3) : for cLUTIs, 75.9% and 75.6%; for complicated pyelonephritis, 81.0% and 92.6%; and for uncomplicated pyelonephritis, 90.4% and 90.7%. Nevertheless, both treatments were highly effective. Doripenem was generally safe for and well tolerated by patients with cUTI, with the rates of incidence and types of TEAEs comparable to those observed in the levofloxacin arm. One safety parameter warrants mention. Seizures have been reported with carbapenems, particularly after treatment of patients with high doses of imipenem (15) . In experimental models, doripenem showed no potential for eliciting seizures or electroencephalogram seizure discharges, unlike other carbapenems tested (5) . In the present study, no patient treated with doripenem had a seizure, although a seizure was reported to have occurred with one patient who received IV levofloxacin.
The results of this study indicate that doripenem may be a valuable option for the parenteral treatment of cUTI, including pyelonephritis, particularly as fluoroquinolone resistance increases over time. The results of in vitro studies show that doripenem has a broad spectrum of activity that includes coverage of the key bacterial uropathogens (3, 8) , including ESBL-producing strains and, as suggested in this study, fluoroquinolone-resistant strains of E. coli. In addition, rising fluoroquinolone resistance has been correlated with an increase in the presence of ESBL-producing pathogens in cases of cUTI (1, 13) . Thus, based on its overall profile, doripenem is likely to become increasingly important for the successful treatment of cUTIs, including pyelonephritis.
